Clatsop County Corrections
Warrenton, Oregon, 97146, United States
NCT Number: NCT07322588
People leaving jail face a very high risk of overdose, especially in the first few weeks after release. Staying on medication for opioid use disorder (MOUD) can greatly reduce this risk, but many people stop treatment during this transition. This study is testing whether a program that offers rewards, called contingency management (CM), can help people stay on MOUD after they return to the community.
In this study, people who are taking MOUD in jail can choose to participate. While still incarcerated, they complete one visit where they may receive a small incentive, such as commissary credit or snacks, for enrolling in the CM program. After they leave jail, participants can earn gift cards when they attend their MOUD appointments and counseling sessions.
Participants may take part in the study for up to three months after release. During this time, they can earn up to $600 in incentives based on their treatment engagement. Researchers will also ask participants to complete a baseline survey and a survey at 3 months. We will also review medical records to confirm whether they continued their MOUD.
The researchers want to learn whether this adapted contingency management program is feasible, acceptable to participants, and helpful for supporting treatment engagement after release from jail. The findings will help determine whether this approach should be tested in a larger study to reduce overdose risk and improve health during the post-release period.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Warrenton, Oregon, 97146, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion criteria
Participants receive gift card rewards for attending MOUD appointments and counseling appointments after release from incarceration.
Time frame: 1, 2, and 3 months
We will assess patient reported receipt of medication for opioid use disorder and also use chart review to determine whether patients are receiving medications and three different time points.
Time frame: 3 months
Number of contingency management sessions attended per participant
Time frame: 3 months
Total dollar amount of contingency management rewards earned by participant throughout the intervention
Time frame: Baseline and 3 months
Participant reported addiction severity using the validated Brief Addiction Monitor, a 17-item, multidimensional progress monitoring tool designed to support the provision of measurement-based care to patients commencing and matriculating through treatment for substance use disorders (SUD). The BAM items assess: (1) Risk for relapse or worsening severity of SUD (Range 0-180 with higher scores indicating higher risk), (2) Protective behaviors that support recovery and resistance to relapse (Range 0-180 with higher score indicating higher protective factors), and (3) Use of alcohol and other substances (Range 0-90 with higher score indicating higher substance use).
Time frame: Baseline and 3 months
Participant reported survey on recovery capital using the validated "Brief Assessment of Recovery Capital (BARC-10)" survey. Score range 10-60 with higher scores indicating higher recovery capital.
Contact information is provided by the study sponsor or research team.
Carol DeFrancesco Senior Research Associate
CONTACT
Linda Peng, MD
CONTACT
Oregon Health and Science University
Other
Enhancing Medication for Opioid Use Disorder Retention With Post-Release Contingency Management
Acronym: RISE-CM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07176351
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07362082
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07725289
Adolescent Substance Use, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT07348796
Chemically-Induced Disorders, Mental Disorders
San Antonio, Texas, United States
View Trial Details